TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37024868
Drug: Cohort B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort B (5 NF135-infected mosquito bites and presumptive treatment with artemether/lumefantrine)
Study: 37024966
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy using balanced crystalloids
Study: 37025256
Drug: Esketamine plus
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine plus oral antidepressant (AD)
Study: 37025758
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg or 480 mg IV) administered for up to 2 years until progression, combined with SRS (15-21 Gy) delivered within 14 days after the first dose of nivolumab.
Study: 37025758
Drug: SRS (15-21
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRS (15-21 Gy) to all un-irradiated BM delivered within 14 days after the first dose of nivolumab.
Study: 37025758
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and SRS combination treatment.
Study: 37026453
Drug: Prescribed aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed aerobic and resistance exercise during neoadjuvant therapy (Arm B)
Study: 37026551
Drug: Sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 200 mg/d
Study: 37026551
Drug: Sacubitril/valsartan 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 400 mg/d
Study: 37026799
Drug: I arm
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: I arm (ibrutinib 420 mg/day for 6 months after 9 months of obinutuzumab-ibrutinib induction)
Study: 37026799
Drug: I-FCG arm
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-FCG arm (up to 4 cycles of fludarabine/cyclophosphamide-obinutuzumab 1000 mg alongside ibrutinib)
Study: 37026822
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping along with physical therapy intervention
Study: 37026822
Drug: Night splinting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night splinting along with physical therapy intervention
Study: 37026822
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention alone (Control)
Study: 37027186
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) - 16-week, thrice-weekly intervention, including a 5-minute warm-up at 10% POmax, 10 sets of alternating 1-minute high-intensity (90% POmax) and 1-minute recovery (10% POmax) intervals, and a 5-minute cooldown (10% POmax)
Study: 37027198
Drug: Blended care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended care intervention for BZRA discontinuation
Study: 37027812
Drug: Investigational immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational immunotherapy agents
Study: 37028103
Drug: Non-tobacco flavored
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-tobacco flavored e-cigarette solutions
Study: 37028103
Drug: Tobacco flavored
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco flavored e-cigarette solutions
Study: 37028103
Drug: Strawberry flavored
Normalized name: SODIUM FLUORIDE 0.122 g in 100 mL DENTAL PASTE [Botao Kids Strawberry Flavored with Fluoride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry flavored e-cigarette solution
Study: 37028433
Drug: Sovleplenib 100
Normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib 100 mg
Study: 37028433
Drug: Sovleplenib 200
Normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib 200 mg
Study: 37028433
Drug: Sovleplenib 300
Normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib 300 mg
Study: 37028433
Drug: Sovleplenib 400
Normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib 400 mg
Study: 37028433
Drug: Sovleplenib 300
Normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib 300 mg (overall response rate)
Study: 37028433
Drug: Sovleplenib 300
Normalized name: Sovleplenib
DrugBank: Sovleplenib (DB17557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib 300 mg (durable response rate)
Study: 37028433
Drug: Sovleplenib (treatment-emergent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib (treatment-emergent adverse events)
Study: 37028614
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer survivors without breast implants
Study: 37028614
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who received breast augmentation surgery
Study: 37029122
Drug: NITD609, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: NITD609, an orally administered PfATPase inhibitor
Study: 37029122
Drug: TD-6450, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD-6450, an orally-administered NS5A hepatitis C virus inhibitor
Study: 37029298
Drug: 111 MBq
Normalized name: dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 111 MBq ± 10% dose
Study: 37029431
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (20 mg/kg bolus + 5 mg/kg continuous infusion)
Study: 37029431
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid (10 mg/kg bolus + 1 mg/kg continuous infusion)
Study: 37029555
Drug: High-dose device-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose device-guided breathing intervention (n=14)
Study: 37029555
Drug: Low-dose device-guided
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose device-guided breathing intervention (n=14)
Study: 37030280
Drug: Maintenance olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance olaparib (400 mg twice daily)
Study: 37030491
Drug: Digital Health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Health Nudging via daily smartphone messages for 12 weeks
Study: 37030570
Drug: Empirical antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotic treatment (cefepime, ceftriaxone, ceftazidime, imipenem, meropenem)
Study: 37030570
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic treatment
Study: 37031462
Drug: CD28/CD27-based CAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD28/CD27-based CAR T-cells therapy
Study: 37031462
Drug: 4-1BB-based CAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-1BB-based CAR T-cells therapy
Study: 37031691
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (50 μg oral daily)
Study: 37031827
Drug: Classical psychedelic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical psychedelic drugs
Study: 37031827
Drug: Non-classical psychedelic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-classical psychedelic drugs
Study: 37032401
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of neoadjuvant sintilimab plus chemotherapy
Study: 37032401
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of neoadjuvant sintilimab plus chemotherapy
Study: 37034122
Drug: Lobeglitazone, empagliflozin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone, empagliflozin, and metformin triple therapy
Study: 37034122
Drug: Empagliflozin and
Normalized name: Empagliflozin and Linagliptin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin and metformin dual therapy
Study: 37034344
Drug: LDL-C 1.8-<2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C 1.8-<2.6 mmol/L
Study: 37034344
Drug: LDL-C ≥2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C ≥2.6 mmol/L
Study: 37034685
Drug: Ivosidenib (AG-120),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (AG-120), an FDA-approved mutant IDH1 inhibitor, used as a wtIDH1 inhibitor under nutrient-deprived conditions.
Study: 37034685
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific agents not mentioned), which induces expression of wtIDH1.
Study: 37035740
Drug: AAV9 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV9 gene therapy, early postnatal administration
Study: 37036155
Drug: Fluconazole 150-mg
Normalized name: fluconazole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 150-mg capsule (test)
Study: 37036155
Drug: Fluconazole 150-mg
Normalized name: fluconazole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 150-mg capsule (reference)
Study: 37036404
Drug: 1-dose HAV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose HAV vaccine
Study: 37036404
Drug: 2-dose HAV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose HAV vaccine administered 4 weeks apart
Study: 37036404
Drug: 2-dose HAV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose HAV vaccine (subgroup analysis)
Study: 37036416
Drug: Lutein (L)
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lutein (L) supplementation
Study: 37036560
Drug: Facilitated subcutaneous
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated subcutaneous immunoglobulin (fSCIG) treatment
Study: 37036671
Drug: AZD8186 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8186 (120 mg BID, 5 days on/2 days off) plus paclitaxel (80 mg/m2, days 1, 8, and 15) every 4 weeks
Study: 37036722
Drug: Avalglucosidase alfa
Normalized name: Avalglucosidase alfa
DrugBank: Avalglucosidase alfa (DB16099)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Avalglucosidase alfa (20 mg/kg by intravenous infusion every other week for 49 weeks)
Study: 37036756
Drug: Riluzole 100
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 100 mg PO BID + Sorafenib 400 mg AM/200 mg PM (MTD)
Study: 37036783
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention for pediatric obesity; details on dosage and duration not available.
Study: 37036843
Drug: Health-coach guided
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-coach guided diet and exercise intervention (16 weekly sessions in family home)
Study: 37037585
Drug: Large tumor-associated
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large tumor-associated macrophages (L-TAMs)
Study: 37037585
Drug: Distribution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distribution of L-TAMs
Study: 37037780
Drug: delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: delgocitinib cream 20 mg/g
Study: 37037780
Drug: cream vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream vehicle
Study: 37037948
Drug: Pen-administered low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pen-administered low-dose dasiglucagon
Study: 37038006
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin (area under the curve 1.5 mg/ml)
Study: 37038005
Drug: Atezolizumab therapy
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab therapy
Study: 37038105
Drug: Guided Self-rehabilitation
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided Self-rehabilitation Contract (GSC) involving daily self-rehabilitation program focusing on three facial muscle groups (Frontalis, Orbicularis oculi, Zygomatici) for six months.
Study: 37038159
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg (UPA15)
Study: 37038159
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg (ADA)
Study: 37039068
Drug: Common workflows
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common workflows for referring clients to treatment
Study: 37039338
Drug: Extemporaneously compounded
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extemporaneously compounded enteral caffeine base solution
Study: 37039792
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment
Study: 37039792
Drug: Lisinopril vs
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril vs Hydrochlorothiazide
Study: 37039792
Drug: Lisinopril vs
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril vs Amlodipine
Study: 37039792
Drug: Lisinopril vs
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril vs Candesartan
Study: 37039791
Drug: TXA-127 (0.5-mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA-127 (0.5-mg/kg intravenous infusion once daily for 5 days)
Study: 37039791
Drug: TRV-027 (12-mg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV-027 (12-mg/h continuous intravenous infusion for 5 days)
Study: 37039790
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (n=231)
Study: 37039948
Drug: faricimab 6
Normalized name: FARICIMAB 6 mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: faricimab 6 mg up to every 16 weeks (Q16W) after 4 initial Q4W doses
Study: 37039948
Drug: aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: aflibercept 2 mg Q8W after 3 initial Q4W doses
Study: 37039967
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1 g twice daily, starting from 5 days preoperatively until 10 days postoperatively)
Study: 37039967
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1 g twice daily)
Study: 37040046
Drug: MK-8353/selumetinib 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353/selumetinib 100/50 mg
Study: 37040046
Drug: MK-8353/selumetinib 150/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353/selumetinib 150/75 mg
Study: 37040046
Drug: MK-8353/selumetinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353/selumetinib (all doses)
Study: 37040046
Drug: MK-8353/selumetinib 50/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8353/selumetinib 50/25 mg and 100/50 mg
Study: 37040086
Drug: Bivalent HPV
Normalized name: HPV, bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent HPV 16/18 vaccine
Study: 37040116
Drug: Lecanemab 10
Normalized name: LECANEMAB 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [LEQEMBI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecanemab 10 mg/kg monthly
Study: 37041046
Drug: Ketamine mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine mouthwash (4 times daily for 2 weeks)
Study: 37041057
Drug: Oral immunonutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunonutritional supplement (INS) for 6 months
Study: 37041057
Drug: Oral immunonutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunonutritional supplement (INS)
Study: 37041081
Drug: Renal replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal replacement therapy during ICU stay
Study: 37041205
Drug: D-Cycloserine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Cycloserine (100 mg) with repeated spaced iTBS
Study: 37041472
Drug: BPI-9016M 300
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPI-9016M 300 mg QD
Study: 37041472
Drug: BPI-9016M 450
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPI-9016M 450 mg QD
Study: 37041472
Drug: BPI-9016M 600
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPI-9016M 600 mg QD
Study: 37041472
Drug: BPI-9016M 400
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPI-9016M 400 mg BID (Part B)
Study: 37041539
Drug: Filapixant 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filapixant 80 mg
Study: 37041539
Drug: Filapixant 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filapixant 250 mg
Study: 37041967
Drug: Other SARS-CoV-2
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other SARS-CoV-2 directed treatment
Study: 37042037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dabrafenib (150 mg twice daily), trametinib (2 mg once daily), and AT13387 (260 mg/m)
Study: 37042037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dabrafenib, trametinib, and AT13387
Study: 37042724
Drug: Chemotherapy (ADjuVANt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ADjuVANt Chemotherapy in the Elderly trial)
Study: 37042921
Drug: Alemtuzumab levels
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab levels ≤0.32 μg/mL
Study: 37042921
Drug: Alemtuzumab levels
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab levels >0.32 μg/mL
Study: 37042921
Drug: Day 0
Normalized name: Apri 28-Day 0.03mg-0.15mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 0 alemtuzumab levels >0.32 μg/mL
Study: 37042921
Drug: CXCL9 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCL9 levels ≤2394 pg/mL (day 14+ median)
Study: 37042921
Drug: CXCL9 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCL9 levels >2394 pg/mL (day 14+)
Study: 37043021
Drug: Robot-assisted cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted cochlear implant surgery (RACIS)
Study: 37043201
Drug: Intrapleural tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural tissue plasminogen activator plus deoxyribonuclease therapy
Study: 37043203
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) with methadone
Study: 37043210
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone (recurrence score <11)
Study: 37043210
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone vs chemotherapy followed by endocrine therapy (recurrence score 11-25)
Study: 37043210
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by endocrine therapy (recurrence score >25)
Study: 37043339
Drug: 1% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% atropine weekly for 6 months
Study: 37043339
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine daily for 6 months (phase 2)
Study: 37043339
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine daily for 1 year (group B)
Study: 37043386
Drug: Baseline high-sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline high-sensitivity troponin T (hsTnT) ≥14 ng/L
Study: 37043386
Drug: 6-predictor model
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-predictor model including age, sex, eGFR <45 mL·min -1 ·1.73 m -2, functional capacity <4 METs or unknown, NT-proBNP ≥300 pg/mL, and estimated intraoperative blood loss
Study: 37043520
Drug: 20 mmol
Normalized name: dibasic potassium phosphate 120 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mmol KCl intravenous injection
Study: 37043518
Drug: Congenital combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed before age 18 years
Study: 37043518
Drug: Congenital combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed <1 year
Study: 37043518
Drug: Congenital combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed 1-17 years
Study: 37043518
Drug: Congenital combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congenital combined pituitary hormone deficiency (cCPHD)
Study: 37043653
Drug: Dersimelagon 100
Normalized name: Dersimelagon
DrugBank: Dersimelagon (DB18007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dersimelagon 100 mg once daily for 16 weeks
Study: 37043653
Drug: Dersimelagon 300
Normalized name: Dersimelagon
DrugBank: Dersimelagon (DB18007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dersimelagon 300 mg once daily for 16 weeks
Study: 37044281
Drug: Oral NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NaCl (2 grams 3 times a day)
Study: 37044281
Drug: Oral NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NaCl